Related Experiment Video
Updated: Mar 1, 2026
08:44
Mouse Heterotopic Cervical Cardiac Transplantation Utilizing Vascular Cuffs
Published on: June 23, 2022
3.7K
Thrombotic complications after hematopoietic stem cell transplantation
1Kansai Medical University, First Department of Internal Medicine.
Summary
Hematopoietic stem cell transplantation (HSCT) complications like graft-versus-host disease (GVHD) are linked to endothelial cell activation. Recombinant thrombomodulin (rTM) may reduce GVHD and endothelial activation, potentially preventing transplant-associated complications.
Area of Science:
- Hematology
- Immunology
- Vascular Biology
Background:
- Hematopoietic stem cell transplantation (HSCT) can lead to serious transplant-associated complications (TACs), including veno-occlusive disease (VOD), thrombotic microangiopathy (TMA), and graft-versus-host disease (GVHD).
- Endothelial cell activation is implicated in the pathogenesis of acute GVHD (aGVHD), a common complication following HSCT.
Purpose of the Study:
- To investigate the association between endothelial cell activation markers and the development of aGVHD after allogeneic HSCT.
- To evaluate the effect of recombinant thrombomodulin (rTM) on endothelial cell activation markers and aGVHD incidence.
Main Methods:
- Measurement of endothelial cell activation markers (sE-selectin, sVCAM-1, PAI-1, microparticles) in patients undergoing allogeneic HSCT.
- Comparison of marker levels between patients who developed aGVHD and those who did not.
- Assessment of aGVHD frequency and marker levels in patients treated with rTM.
Main Results:
- Significantly higher levels of endothelial cell activation markers were observed in patients who developed aGVHD compared to those who did not.
- Patients receiving rTM showed a significantly lower frequency of aGVHD.
- Treatment with rTM was associated with reduced levels of endothelial cell activation markers.
Conclusions:
- Endothelial cell activation appears to be linked to transplant-associated complications, specifically aGVHD, following HSCT.
- Recombinant thrombomodulin (rTM) may mitigate aGVHD and associated endothelial cell activation, suggesting a potential therapeutic role in preventing TACs.
Related Concept Videos
01:24Disorders of Hemostasis
2.4K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.4K
01:30Venous Thrombosis I: Introduction
580
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
580
01:29Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
01:22Bone Marrow Sampling and Transplants
1.8K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
1.8K
01:21Stem Cell Therapy for Tissue Regeneration
4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
01:30Venous Thrombosis IV: Nursing Management
324
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
324